Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Novartis, Astellas Intend To Disprove Eczema Treatments’ Cancer Risk

Jan 19 2006

• By Bowman Cox

Related Content

"Black Box" For Protopic, Elidel Is "Blunt" But Necessary Instrument, Advisory Cmte. Says

Feb 16 2005

Novartis' Elidel, Fujisawa's Protopic To Add "Black Box" On Cancer Risk

Mar 10 2005

FDA Approves Boxed Warning On Cancer Risk For Elidel And Protopic

Jan 19 2006

Additional Topics

BioPharmaceutical

More from Archive

More from Pink Sheet

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window